An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy with MSC1936369B and SAR245409 in Subjects with Locally Advanced or Metastatic Solid Tumors
Determine the Maximum Tolerated Dose (MTD) of the study drug combination (MSC1936369B and SAR245409)
Locally advanced or metastatic solid tumors
1. Advanced solid tumor for which there is no approved therapy
2. Measurable or evaluable disease
3. Aged 18 or older
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression, unacceptable side effects, investigator's decision, or withdrawal by subject.
Knight Clinical Trials Information Line
EMD Serono, Inc.